DK2552955T3 - Antistoffer med modificeret affinitet til FCRN, som fremmer antigen-clearance - Google Patents

Antistoffer med modificeret affinitet til FCRN, som fremmer antigen-clearance Download PDF

Info

Publication number
DK2552955T3
DK2552955T3 DK11714860.1T DK11714860T DK2552955T3 DK 2552955 T3 DK2552955 T3 DK 2552955T3 DK 11714860 T DK11714860 T DK 11714860T DK 2552955 T3 DK2552955 T3 DK 2552955T3
Authority
DK
Denmark
Prior art keywords
antigen
amino acid
binding
antibody
human fcrn
Prior art date
Application number
DK11714860.1T
Other languages
English (en)
Inventor
Tomoyuki Igawa
Shinya Ishii
Atsuhiko Maeda
Takashi Nakai
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44260244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2552955(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK2552955T3 publication Critical patent/DK2552955T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Photolithography (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Slot Machines And Peripheral Devices (AREA)

Claims (14)

1. Antistof omfattende et antigen-bindende domæne og et humant FcRn-bindende domæne, som har en FcRn-bindende aktivitet ved pH 5,5 og ved pH 7,0, og en lavere antigen-bindende aktivitet ved pH 5,5 end ved pH 7,0, hvor den humane FcRn-bindende aktivitet ved pH 7,0 og ved 25°C er stærkere end KD 3,2 μΜ, hvor det humane FcRn-bindende domæne er et Fc domæne, som resulterer ved substitution af i det mindste én aminosyre i Fc domænet i et humant lgG1, lgG2, lgG3 eller lgG4 med en anden aminosyre.
2. Antistof ifølge krav 1, hvor forholdet imellem antigen-bindende aktivitet ved pH 5,5 og ved pH 7,0 er i det mindste 2 for værdien af KD (ved pH 5,5)/KD (ved pH 7,0).
3. Antistof ifølge krav 1 eller 2, som omfatter en aminosyremutation af det antigenbindende domæne, som omfatter en substitution af i det mindste én aminosyre i det antigen-bindende domæne med histidin eller indsætningen af i det mindste ét histidin.
4. Antistof ifølge ethvert af kravene 1 til 3, hvor det antigen-bindende domæne er opnået fra et antigen-bindende domæne bibliotek.
5. Antistof ifølge ethvert af kravene 1 til 4, hvor det humane FcRn-bindende domæne er et humant FcRn-bindende domæne omfattende en aminosyresekvens med en substitution af i det mindste én aminosyre valgt blandt disse i positionerne 237, 238, 239, 248, 250, 252, 254, 255, 256, 257, 258, 265, 270, 286, 289, 297, 298, 303, 305, 307, 308, 309, 311, 312, 314, 315, 317, 325, 332, 334, 360, 376, 380, 382, 384, 385, 386, 387, 389, 424, 428, 433, 434 og 436 (EU nummerering) i Fc domænet i et humant lgG1, lgG2, lgG3 eller lgG4 med en anden aminosyre.
6. Antistof ifølge ethvert af kravene 1 til 5, som omfatter et humant FcRn-bindende domæne omfattende aminosyresubstitution i Fc domænet i humant lgG1, lgG2, lgG3 eller lgG4, som omfatter i det mindste én aminosyresubstitution valgt blandt: en aminosyresubstitution af Gly med Met ved position 237; en aminosyresubstitution af Pro med Ala ved position 238; en aminosyresubstitution af Ser med Lys ved position 239; en aminosyresubstitution af Lys med Ile ved position 248; en aminosyresubstitution af Thr med Ala, Phe, Ile, Met, Gin, Ser, Val, Trp eller Tyr ved position 250; en aminosyresubstitution af Met med Phe, Trp eller Tyr ved position 252; en aminosyresubstitution afSer med Thr ved position 254; en aminosyresubstitution af Arg med Glu ved position 255; en aminosyresubstitution af Thr med Asp, Glu eller Gin ved position 256; en aminosyresubstitution af Pro med Ala, Gly, Ile, Leu, Met, Asn, Ser, Thr eller Val ved position 257; en aminosyresubstitution af Glu med His ved position 258; en aminosyresubstitution af Asp med Ala ved position 265; en aminosyresubstitution af Asp med Phe ved position 270; en aminosyresubstitution af Asn med Ala eller Glu ved position 286; en aminosyresubstitution af Thr med His ved position 289; en aminosyresubstitution af Asn med Ala ved position 297; en aminosyresubstitution af Ser med Gly ved position 298; en aminosyresubstitution af Val med Ala ved position 303; en aminosyresubstitution af Val med Ala ved position 305; en aminosyresubstitution af Thr med Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gin, Arg, Ser, Val, Trp eller Tyr ved position 307; en aminosyresubstitution af Val med Ala, Phe, Ile, Leu, Met, Pro, Gin eller Thr ved position 308; en aminosyresubstitution af Leu eller Val med Ala, Asp, Glu, Pro eller Arg ved position 309; en aminosyresubstitution af Gin med Ala, His eller Ile ved position 311; en aminosyresubstitution af Asp med Ala eller His ved position 312; en aminosyresubstitution af Leu med Lys eller Arg ved position 314; en aminosyresubstitution af Asn med Ala eller His ved position 315; en aminosyresubstitution af Lys med Ala ved position 317; en aminosyresubstitution af Asn med Gly ved position 325; en aminosyresubstitution af Ile med Val ved position 332; en aminosyresubstitution af Lys med Leu ved position 334; en aminosyresubstitution af Lys med His ved position 360; en aminosyresubstitution af Asp med Ala ved position 376; en aminosyresubstitution af Glu med Ala ved position 380; en aminosyresubstitution af Glu med Ala ved position 382; en aminosyresubstitution af Asn eller Ser med Ala ved position 384; en aminosyresubstitution af Gly med Asp eller His ved position 385; en aminosyresubstitution af Gin med Pro ved position 386; en aminosyresubstitution af Pro med Glu ved position 387; en aminosyresubstitution af Asn med Ala eller Served position 389; en aminosyresubstitution af Ser med Ala ved position 424; en aminosyresubstitution af Met med Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Asn, Pro, Gin, Ser, Thr, Val, Trp eller Tyr ved position 428; en aminosyresubstitution af His med Lys ved position 433; en aminosyresubstitution af Asn med Ala, Phe, His, Ser, Trp eller Tyr ved position 434; og en aminosyresubstitution af Tyr med His eller Phe ved position 436 i EU nummereringen.
7. Antistof ifølge ethvert af kravene 1 til 5, hvis humane FcRn-bindende domæne omfatter i et mindste én aminosyre valgt blandt: Met ved aminosyreposition 237; Ala ved aminosyreposition 238; Lys ved aminosyreposition 239; Ile ved aminosyreposition 248; Ala, Phe, Ile, Met, Gin, Ser, Val, Trp eller Tyr ved aminosyreposition 250; Phe, Trp eller Tyr ved aminosyreposition 252; Thrved aminosyreposition 254; Glu ved aminosyreposition 255; Asp, Glu eller Gin ved aminosyreposition 256; Ala, Gly, Ile, Leu, Met, Asn, Ser, Thr eller Val ved aminosyreposition 257; His ved aminosyreposition 258; Ala ved aminosyreposition 265; Phe ved aminosyreposition 270; Ala eller Glu ved aminosyreposition 286; His ved aminosyreposition 289; Ala ved aminosyreposition 297; Gly ved aminosyreposition 298; Ala ved aminosyreposition 303; Ala ved aminosyreposition 305; Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gin, Arg, Ser, Val, Trp eller Tyr ved aminosyreposition 307; Ala, Phe, Ile, Leu, Met, Pro, Gin eller Thr ved aminosyreposition 308; Ala, Asp, Glu, Pro eller Arg ved aminosyreposition 309; Ala, His eller Ile ved aminosyreposition 311; Ala eller His ved aminosyreposition 312; Lys eller Arg ved aminosyreposition 314; Ala eller His ved aminosyreposition 315; Ala ved aminosyreposition 317; Gly ved aminosyreposition 325; Val ved aminosyreposition 332; Leu ved aminosyreposition 334; His ved aminosyreposition 360; Ala ved aminosyreposition 376; Ala ved aminosyreposition 380; Ala ved aminosyreposition 382; Ala ved aminosyreposition 384; Asp eller His ved aminosyreposition 385; Pro ved aminosyreposition 386; Glu ved aminosyreposition 387; Ala eller Ser ved aminosyreposition 389; Ala ved aminosyreposition 424; Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Asn, Pro, Gin, Ser, Thr, Val, Trp eller Tyr ved aminosyreposition 428; Lys ved aminosyreposition 433; Ala, Phe, His, Ser, Trp eller Tyr ved aminosyreposition 434; og His eller Phe som en aminosyre ved position 436 (EU nummerering) i Fc domænet i humant lgG1, lgG2, lgG3 eller lgQ4.
8. Antistof ifølge ethvert af kravene 1 til 7, som har en antagonistisk aktivitet.
9. Antistof ifølge ethvert af kravene 1 til 8, som binder til et menbranantigen eller opløseligt antigen.
10. Antistof ifølge ethvert af kravene 1 til 9, hvor antistoffet er valgt blandt et kimærisk antistof, et humaniseret antistof eller et humant antistof.
11. Farmaceutisk sammensætning omfattende et antistof ifølge ethvert af kravene 1 til 10.
12. Fremgangsmåde til fremstilling af et antistof, som omfatter følgende trin: (a) udvælgelse af et antistof, som har en stærkere human FcRn-bindingsaktivitet ved pH 7,0 end før ændring af i det mindste én aminosyre i det humane FcRn-bindende domæne i antistoffet, som har en human FcRn-bindingsaktivitet ved pH 5,5; (b) ændring af i det mindste én aminosyre i det antigen-bindende domæne i et antistof og udvælgelse af et antistof, som har en stærkere antigen-bindende aktivitet ved pH 7,0 end ved pH 5,5; (c) tilvejebringelse af et gen, som koder for et antistof, hvori et humant FcRn-bindende domæne og et antigen-bindende domæne fremstillet ved (a) og (b) er forbundet; og (d) fremstilling af et antistof under anvendelse af genet fremstillet ved (c).
13. Fremgangsmåde til fremstilling af et antistof, som omfatter følgende trin: (a) udvælgelse af et antistof, som har en stærkere human FcRn-bindingsaktivitet ved pH 7,0 end før ændring af i det mindste én aminosyre i det humane FcRn-bindingsdomæne i antistoffet, som har en human FcRn-bindingsaktivitet ved pH 5,5; (b) udvælgelse af et antistof, som har en stærkere antigen-bindende aktivitet ved pH 7,0 end ved pH 5,5; (c) tilvejebringelse af et gen, som koder for et antistof, hvori et humant FcRn-bindende domæne og et antigen-bindende domæne fremstillet ved (a) og (b) er forbundet; og (d) fremstilling af et antistof under anvendelse af genet fremstillet ved (c).
14. Fremgangsmåde til screening for et antistof, som omfatter følgende trin: (a) udvælgelse af et antistof, som har stærkere human FcRn-bindingsaktivitet ved pH 7,0 end før ændring af i det mindste én aminosyre i det humane FcRn-bindingsdomæne for antistoffet, som har en human FcRn-bindingsaktivitet ved pH 5,5; og (b) ændring af i det mindste én aminosyre i det antigen-bindende domæne for et antistof og udvælgelse af et antistof, som har en stærkere antigen-bindende aktivitet ved pH 7,0 end ved pH 5,5.
DK11714860.1T 2010-03-30 2011-03-30 Antistoffer med modificeret affinitet til FCRN, som fremmer antigen-clearance DK2552955T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010079667 2010-03-30
JP2010250830 2010-11-09
PCT/JP2011/001888 WO2011122011A2 (en) 2010-03-30 2011-03-30 Antibodies with modified affinity to fcrn that promote antigen clearance

Publications (1)

Publication Number Publication Date
DK2552955T3 true DK2552955T3 (da) 2017-08-21

Family

ID=44260244

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11714860.1T DK2552955T3 (da) 2010-03-30 2011-03-30 Antistoffer med modificeret affinitet til FCRN, som fremmer antigen-clearance

Country Status (21)

Country Link
US (6) US20130131319A1 (da)
EP (4) EP2552955B1 (da)
JP (8) JP5415624B2 (da)
KR (6) KR101831464B1 (da)
CN (2) CN113307868A (da)
AU (1) AU2011233390B2 (da)
BR (1) BR112012024710B1 (da)
CA (1) CA2794860C (da)
DK (1) DK2552955T3 (da)
ES (3) ES2995193T3 (da)
HR (3) HRP20171080T1 (da)
HU (3) HUE069214T2 (da)
LT (1) LT2552955T (da)
MX (1) MX2012011338A (da)
PL (3) PL3702368T3 (da)
PT (2) PT2552955T (da)
RU (1) RU2745989C9 (da)
SG (2) SG184163A1 (da)
SI (2) SI3181581T1 (da)
TW (2) TWI667257B (da)
WO (1) WO2011122011A2 (da)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) * 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
EP2698431B1 (en) * 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
BR112014007484A2 (pt) 2011-09-30 2017-04-04 Chugai Pharmaceutical Co Ltd molécula de ligação a antígeno de indução de resposta imune a antígeno alvo
WO2013047752A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 抗原の消失を促進する抗原結合分子
CA3233142A1 (en) * 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
PL2814587T3 (pl) 2012-02-15 2018-10-31 F.Hoffmann-La Roche Ag Chromatografia powinowactwa oparta na receptorze Fc
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
DK2825036T3 (da) * 2012-03-16 2018-07-16 Regeneron Pharma Histidinmanipulerede letkædeantistoffer og genetisk modificerede gnavere til generering heraf
HK1200271A1 (en) 2012-03-16 2015-08-07 瑞泽恩制药公司 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
HK1207654A1 (en) 2012-04-27 2016-02-05 Bioatla, Llc Modified antibody regions and uses thereof
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
SG10202006507XA (en) * 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
GB201302878D0 (en) * 2013-02-19 2013-04-03 Argen X Bv Modified igG molecules
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
EP2992010B1 (en) 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
BR112016006502A2 (pt) 2013-09-30 2017-09-19 Chugai Pharmaceutical Co Ltd Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado
TWI652279B (zh) 2013-11-11 2019-03-01 中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
BR112016014969A2 (pt) 2014-01-15 2018-01-23 Hoffmann La Roche polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
EP3119490B1 (en) 2014-03-21 2021-09-08 F. Hoffmann-La Roche AG In vitro prediction of in vivo half-life of antibodies
EP3142700B1 (en) * 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
CA2946430A1 (en) * 2014-06-12 2015-12-17 F. Hoffmann-La Roche Ag Method for selecting antibodies with modified fcrn interaction
FR3024453B1 (fr) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016071377A1 (en) * 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
US10307480B2 (en) * 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP3215528B1 (en) * 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
EP4632120A3 (en) 2014-11-11 2026-01-07 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107428823B (zh) 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
PT3922645T (pt) * 2015-09-15 2025-05-29 Scholar Rock Inc ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
CN108271372B (zh) 2015-09-18 2021-07-09 中外制药株式会社 Il-8-结合抗体及其应用
EP3390443A4 (en) 2015-12-18 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
MA43773B1 (fr) * 2016-03-14 2026-01-30 Universitetet I Oslo Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
AU2017269839A1 (en) 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
MX2018014375A (es) 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y metodos de uso.
FI3494134T3 (fi) * 2016-08-02 2026-02-19 Visterra Inc Muunneltuja polypeptidejä ja niiden käyttötapoja
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
MA45919A (fr) * 2016-08-12 2019-06-19 Janssen Biotech Inc Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
BR112019007281A2 (pt) 2016-10-14 2019-07-09 Xencor Inc proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
EP3569615A4 (en) * 2017-01-13 2020-07-29 Hanx Biopharmaceutics, Inc PROCESS FOR IMPROVING THE BINDING AFFINITY OF AN IGG ANTIBODY TOWARDS FCRN AND PROLONGING THE SERIC HALF-LIFE OF THE latter
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
CR20190403A (es) 2017-01-31 2019-10-10 Hoffmann La Roche Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
AU2018218345B2 (en) * 2017-02-10 2025-04-03 Genmab B.V. Polypeptide variants and uses thereof
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
WO2018186717A1 (ko) 2017-04-07 2018-10-11 국민대학교 산학협력단 혈중 반감기 향상을 위한 항체 Fc 변이체들
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
AU2018281045A1 (en) * 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
BR112020001703B1 (pt) 2017-07-27 2024-01-02 Alexion Pharmaceuticals, Inc Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
JP7191087B2 (ja) 2017-08-11 2022-12-16 リサーチ ディベロップメント ファウンデーション 血清中半減期の増強のための操作された抗体ｆｃバリアント
CN111315213B (zh) 2017-10-06 2023-09-12 普罗塞纳生物科学有限公司 抗甲状腺素运载蛋白抗体
PE20210042A1 (es) 2017-10-06 2021-01-08 Prothena Biosciences Ltd Metodos para detectar transtiretina
US12235261B2 (en) 2017-10-20 2025-02-25 Chugai Seiyaku Kabushiki Kaisha Method for measuring cellular uptake of molecules
EP3700928A1 (en) 2017-10-26 2020-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
EP3746122A4 (en) * 2018-02-02 2021-11-24 OncoC4, Inc. SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODY SELECTION AND DESIGN PROCESSES FOR CANCER THERAPY
AU2019214865B2 (en) 2018-02-02 2025-04-10 OncoC4, Inc. Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
WO2019190990A1 (en) * 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN120209132A (zh) * 2018-04-13 2025-06-27 中外制药株式会社 抗补体组分抗体及使用方法
JP7516254B2 (ja) 2018-04-18 2024-07-16 ゼンコア インコーポレイテッド Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
KR20210003813A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
MX2020012091A (es) 2018-05-14 2021-04-28 Oncoimmune Inc Composiciones anti-cd24 y usos de las mismas.
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
GB201809341D0 (en) * 2018-06-07 2018-07-25 Ucb Biopharma Sprl Multi-domain proteins with increased native state colloidal stability
JP7397444B2 (ja) 2018-06-26 2023-12-13 協和キリン株式会社 コンドロイチン硫酸プロテオグリカン－５に結合する抗体
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
EP3814373A1 (en) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MX2021000532A (es) 2018-07-19 2021-04-12 Regeneron Pharma Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
IL280475B2 (en) 2018-08-01 2026-04-01 Chugai Pharmaceutical Co Ltd Pharmaceutical preparation for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
CR20210239A (es) 2018-10-12 2021-12-15 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
MX2021004994A (es) 2018-10-30 2021-06-15 Alexion Pharma Inc Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
CN113227131B (zh) 2018-12-20 2025-03-04 豪夫迈·罗氏有限公司 经修饰的抗体Fc及其使用方法
CN113613676A (zh) 2019-03-19 2021-11-05 中外制药株式会社 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
AU2020273072B2 (en) 2019-04-10 2026-01-22 Chugai Seiyaku Kabushiki Kaisha Method for purifying Fc region-modified antibody
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
JPWO2020213724A1 (da) * 2019-04-19 2020-10-22
CN114096562B (zh) 2019-05-15 2025-02-21 中外制药株式会社 抗原结合分子、药物组合物和方法
CA3142886A1 (en) * 2019-06-06 2020-12-10 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
CN114786732A (zh) * 2019-06-06 2022-07-22 神话治疗股份有限公司 抗原结合蛋白构建体及其用途
CN114746115A (zh) * 2019-06-07 2022-07-12 神话治疗股份有限公司 抗原结合蛋白构建体及其用途
CA3146379A1 (en) * 2019-07-08 2021-01-14 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
US20220281984A1 (en) * 2019-07-30 2022-09-08 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
AU2020330307A1 (en) * 2019-08-12 2022-03-17 CSL Innovation Pty Ltd Complement C2 binding proteins and uses thereof
CN114746120B (zh) 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
CN114728175A (zh) * 2019-10-04 2022-07-08 神话治疗股份有限公司 抗原结合性蛋白构建体和其用途
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US12600778B2 (en) * 2019-10-31 2026-04-14 The Research Foundation For The State University Of New York Rage antibodies, fragments and uses thereof
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
KR102645629B1 (ko) 2019-12-27 2024-03-07 추가이 세이야쿠 가부시키가이샤 항ctla-4 항체 및 그의 사용
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US20230072197A1 (en) * 2020-01-29 2023-03-09 Korea University Research And Business Foundation Ph-sensitive fc variants
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP4133269A1 (en) * 2020-04-08 2023-02-15 F. Hoffmann-La Roche AG Large molecule unspecific clearance assay
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
WO2022044248A1 (ja) 2020-08-28 2022-03-03 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
CN120309734A (zh) 2021-01-13 2025-07-15 威特拉公司 人源化补体5a受体1抗体和其使用方法
EP4494660A3 (en) * 2021-02-03 2025-04-16 Mythic Therapeutics, Inc. Anti-met antibodies and uses thereof
WO2022263501A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
AR126220A1 (es) 2021-06-25 2023-09-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-ctla-4
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
TW202527987A (zh) 2021-06-25 2025-07-16 日商中外製藥股份有限公司 抗ctla-4抗體的用途
CN115572331A (zh) * 2021-07-06 2023-01-06 联邦生物科技(珠海横琴)有限公司 一种具有增强FcRn受体结合的突变子
CA3229487A1 (en) * 2021-08-20 2023-02-23 Adam WAICKMAN Iga monoclonal antibodies for treating flavivirus infection
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
AU2024242538A1 (en) * 2023-03-24 2025-10-30 Paragon Therapeutics, Inc. Fc fragments that bind fcrn and methods of use
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
WO2025260124A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd MULTIFUNCTIONAL FcRn ANTAGONISTS AND USES THEREOF
FR3167160A1 (fr) 2024-10-08 2026-04-10 Alga Biologics Immunoglobulines avec affinite augmentee pour le fcrn
CN120365429B (zh) * 2025-06-30 2025-09-05 上海交通大学医学院附属仁济医院 Cd70特异性纳米抗体、分子影像探针及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS63149900A (ja) 1986-12-15 1988-06-22 Toshiba Corp 半導体メモリ
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
EP0732404A4 (en) 1993-12-03 1997-07-30 Asahi Chemical Ind NEW EXPRESSION DETECTION VECTOR
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100940380B1 (ko) * 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
EP2385069A3 (en) * 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
DE102004032634A1 (de) 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
WO2006031370A2 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
CN101600793B (zh) 2006-05-19 2013-06-26 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
CA2712432C (en) * 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
EP2275443B1 (en) * 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
JP5028372B2 (ja) 2008-09-26 2012-09-19 京セラドキュメントソリューションズ株式会社 画像処理装置、画像処理方法及び画像処理プログラム
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR101834999B1 (ko) * 2008-10-14 2018-03-06 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
AU2010201495B2 (en) 2009-04-16 2012-04-12 Accenture Global Services Limited Touchpoint customization system
PL3053932T3 (pl) * 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
BR112012022917A2 (pt) * 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
ES2926376T3 (es) 2014-06-30 2022-10-25 Merck Patent Gmbh Anticuerpos anti-TNFa con unión al antígeno dependiente del pH

Also Published As

Publication number Publication date
WO2011122011A3 (en) 2012-01-05
EP2552955B1 (en) 2017-05-03
US20130131319A1 (en) 2013-05-23
KR20180019764A (ko) 2018-02-26
JP2014065708A (ja) 2014-04-17
CN102918057A (zh) 2013-02-06
JP2021091725A (ja) 2021-06-17
PL2552955T3 (pl) 2017-12-29
TW201700499A (zh) 2017-01-01
SG10201703798YA (en) 2017-06-29
SI2552955T1 (sl) 2017-08-31
KR20210079407A (ko) 2021-06-29
PL3181581T3 (pl) 2025-02-10
RU2012146098A (ru) 2014-05-10
WO2011122011A2 (en) 2011-10-06
US20160244526A1 (en) 2016-08-25
KR20240094003A (ko) 2024-06-24
JP2019178134A (ja) 2019-10-17
EP2552955A2 (en) 2013-02-06
PT3181581T (pt) 2024-11-21
KR20130010002A (ko) 2013-01-24
CA2794860C (en) 2022-05-17
EP3702368A1 (en) 2020-09-02
EP3181581B1 (en) 2024-09-25
MX2012011338A (es) 2012-11-30
KR101831464B1 (ko) 2018-02-22
HUE069214T2 (hu) 2025-02-28
KR102468436B1 (ko) 2022-11-17
US20170002080A1 (en) 2017-01-05
PL3702368T3 (pl) 2025-03-24
JP2013528354A (ja) 2013-07-11
JP2017036318A (ja) 2017-02-16
JP2023022203A (ja) 2023-02-14
JP6029252B2 (ja) 2016-11-24
HRP20171080T1 (hr) 2017-10-06
ES2995193T3 (en) 2025-02-07
BR112012024710A8 (pt) 2021-06-08
KR102269707B1 (ko) 2021-06-25
TW201202419A (en) 2012-01-16
LT2552955T (lt) 2017-07-25
RU2745989C2 (ru) 2021-04-05
ES2633597T3 (es) 2017-09-22
TWI667346B (zh) 2019-08-01
JP5913243B2 (ja) 2016-04-27
JP2025081443A (ja) 2025-05-27
TWI667257B (zh) 2019-08-01
SI3181581T1 (sl) 2025-02-28
JP7186813B2 (ja) 2022-12-09
EP4501956A2 (en) 2025-02-05
HRP20241779T1 (hr) 2025-02-28
HUE069966T2 (hu) 2025-04-28
EP3702368C0 (en) 2024-11-20
US20170226206A1 (en) 2017-08-10
KR101974794B1 (ko) 2019-05-02
KR20220157513A (ko) 2022-11-29
JP6850317B2 (ja) 2021-03-31
ES2989715T3 (es) 2024-11-27
JP2016145222A (ja) 2016-08-12
EP3181581A1 (en) 2017-06-21
AU2011233390A1 (en) 2012-11-08
BR112012024710A2 (pt) 2021-04-27
CA2794860A1 (en) 2011-10-06
JP6518222B2 (ja) 2019-05-22
US20230220083A1 (en) 2023-07-13
RU2745989C9 (ru) 2021-09-10
EP4501956A3 (en) 2025-11-26
EP3702368B1 (en) 2024-11-20
US20170002066A1 (en) 2017-01-05
SG184163A1 (en) 2012-10-30
CN102918057B (zh) 2021-06-01
JP5415624B2 (ja) 2014-02-12
CN113307868A (zh) 2021-08-27
KR20190047111A (ko) 2019-05-07
HRP20241623T1 (hr) 2025-02-14
HUE033812T2 (en) 2018-01-29
AU2011233390B2 (en) 2015-08-20
PT2552955T (pt) 2017-07-12
BR112012024710B1 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
US20230220083A1 (en) Antibodies with modified affinity to fcrn that promote antigen clearance
RU2810471C1 (ru) АНТИТЕЛА С МОДИФИЦИРОВАННОЙ АФФИННОСТЬЮ К FcRn, КОТОРЫЕ УВЕЛИЧИВАЮТ КЛИРЕНС АНТИГЕНОВ
KR20260047649A (ko) 항원 제거를 촉진하는 ＦｃＲｎ에 대해 변경된 친화성을 갖는 항체